Skip to Content

Korlym (mifepristone) Disease Interactions

There are 6 disease interactions with Korlym (mifepristone):

Major

Mifepristone (applies to Korlym) organ transplant

Major Potential Hazard, High plausibility.

Mifepristone is contraindicated in patients with serious medical conditions, such as patients requiring treatment with systemic corticosteroids for immunosuppression after organ transplantation. Mifepristone antagonizes the effects of glucocorticoids.

Major

Mifepristone (applies to Korlym) vaginal bleeding

Major Potential Hazard, Moderate plausibility. Applicable conditions: Endometrial Dysplasia, Abnormal Uterine Bleeding, Bleeding Associated with Coagulation Defect

Mifepristone is contraindicated in women with unexplained vaginal bleeding, and women with endometrial hyperplasia with atypia or endometrial carcinoma, as it promotes endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding. It should also be used with caution in women with hemorrhagic disorders or those receiving anticoagulation therapy.

Moderate

Mifepristone (applies to Korlym) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Mifepristone does not reduce serum cortisol levels, and elevated cortisol levels might activate mineralocorticoid receptors which are expressed in cardiac tissue. Caution should be used in patients with underlying heart conditions, including heart failure and coronary vascular disease.

Moderate

Mifepristone (applies to Korlym) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

There is limited information on the safety of mifepristone in patients with mild to moderate hepatic impairment, hence the manufacturers recommend that the maximum dose should not exceed 600 mg per day. The use of mifepristone is not recommended in patients with severe hepatic disease as the pharmacokinetics in these patients have not been studied.

Moderate

Mifepristone (applies to Korlym) long QT

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Mifepristone prolongs the QTc interval in a dose-related manner. There is little or no experience with high exposure, concomitant dosing with other QT- prolonging drugs, or potassium channel variants resulting in long QT interval. Caution and monitoring is advised if used in patients with long QT. To minimize risk, the lowest effective dose should always be used.

Moderate

Mifepristone (applies to Korlym) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

No change in the initial dose of mifepristone is needed for renal impairment; but the manufacturers recommend that the maximum dose should not exceed 600 mg per day in these patients.

Korlym (mifepristone) drug interactions

There are 571 drug interactions with Korlym (mifepristone)

Korlym (mifepristone) alcohol/food interactions

There is 1 alcohol/food interaction with Korlym (mifepristone)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.